• Mean age at baseline was 30.7 years, mean disease duration was 5.5 years, mean EDSS was 1.8 and mean annualised relapse rate before study entry was 1.7. (bmj.com)
  • Lemtrada is indicated for adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features. (genengnews.com)
  • The European Union approved Lemtrada following two Phase III studies comparing the treatment to high-dose subcutaneous interferon beta-1a (Rebif®) in patients with RRMS who had active disease and were either new to treatment (CARE-MS I) or who had relapsed while on prior therapy (CARE-MS II). (genengnews.com)
  • The Lemtrada clinical trial data support its potential to meaningfully address disability in active RRMS patients, while Aubagio's efficacy, safety, and convenient dosing may provide an important alternative to injectable therapies," Hans-Peter Hartung, M.D., Ph.D., professor and chairman of the department of neurology at Heinrich-Heine-University in Duesseldorf, Germany, said in a statement. (genengnews.com)
  • In the 12-month phase 3 TRANSFORMS study, fingolimod showed greater efficacy than intramuscular interferon beta (IFNβ)-1a in patients with relapsing-remitting multiple sclerosis (RRMS). (nih.gov)
  • Cerebrospinal fluid (CSF) and serum concentrations, quantitative intrathecal synthesis, oligoclonal bands (OCB) patterns and affinity distributions of anti-Epstein Barr virus (EBV) antibodies were evaluated in 100 relapsing-remitting MS (RRMS) patients and 200 age- and sex-matched controls with other inflammatory neurological disorders (OIND) and other noninflammatory neurological disorders (NIND). (biomedcentral.com)
  • Thirty-four MS patients (7 with secondary progressive MS [SPMS], 27 with relapsing remitting MS [RRMS]) and 30 healthy volunteers, genetically stratified for translocator protein (TSPO) binding status, underwent PET scanning with TSPO radioligands ( 11 C-PBR28 or 18 F-PBR111). (snmjournals.org)
  • A higher proportion of lesions were inactive in patients with SPMS (35%) than RRMS (23%), but active lesions were found in all patients, including those on highly efficacious treatments. (snmjournals.org)
  • Active lesions were found in patients with both RRMS and SPMS. (snmjournals.org)
  • Background: Simultaneous comparisons of multiple disease-modifying therapies for relapsing-remitting multiple sclerosis (RRMS) over an extended follow-up are lacking. (unipr.it)
  • Conclusions: The effectiveness of natalizumab and fingolimod in active RRMS is superior to dimethyl fumarate, teriflunomide, glatiramer acetate and interferon beta. (unipr.it)
  • Siponimod is one of several disease-modifying therapies used in the management of relapsing forms of MS. Although not curative, these therapies have all been shown to modify several measures of disease activity, including relapse rates, new or enhancing MRI lesions, and disability progression. (drugs.com)
  • MRIs will be performed with and without contrast dye to locate lesions and highlight active inflammation. (healthline.com)
  • Even early on, this test may reveal active inflammation or lesions. (healthline.com)
  • Background: Interferon beta (IFNB) is available in parenteral formulations for treatment of multiple sclerosis (MS). The purpose of this study was to evaluate safety, tolerability and effects on MRI lesions of three different doses of oral IFNB-1a compared with placebo over six months in relapsing-remitting (RR) MS patients. (amsterdamumc.org)
  • The primary variable was the cumulative number of newly active lesions. (amsterdamumc.org)
  • Median cumulative numbers of newly active lesions over six months were 4.0 in the placebo and 0.6 MIU groups, compared with 7.5 and 9.0 in the 0.06 and 6 MIU groups (no significant differences). (amsterdamumc.org)
  • T1 lesions, as measured by MRI, are a marker of active inflammation and T2 lesions represent the amount of disease burden or lesion load. (gene.com)
  • It has been suggested to regard incidental findings of demyelinating lesions in MRI in individuals without any history of clinical symptoms consistent with neurological dysfunction, so-called radiological isolated syndrome, as the initial course of multiple sclerosis. (ku.dk)
  • if multiple lesions occur, change injection site or discontinue BETASERON until healing of skin lesions. (nih.gov)
  • Analyses of efficacy included annualized relapse rate (ARR), and magnetic resonance imaging (MRI) measures [gadolinium (Gd)-enhancing T1 lesions, new/newly enlarged (active) T2 lesions, brain volume change]. (nih.gov)
  • Fingolimod also reduced the number of new Gd-enhancing lesions, active T2 lesions, and the rate of brain volume loss, versus IFNβ-1a in most (95 %) subgroups. (nih.gov)
  • The objective of this study was to assess microglial activation in lesions and in normal-appearing white matter (NAWM) of multiple sclerosis (MS) patients using PET. (snmjournals.org)
  • White matter lesions (WMLs) were classified as "active" (DVR highest in the lesion), "peripherally active" (perilesional DVR highest), "inactive" (DVR highest in surrounding NAWM), or "undifferentiated" (similar DVR across lesion, perilesional and NAWM volumes). (snmjournals.org)
  • Multiple sclerosis (MS) is a chronic disease of the central nervous system characterized by multifocal inflammatory demyelinating lesions. (snmjournals.org)
  • With this in mind, most HSCT research and treatment centers restrict the treatment to patients with active inflammatory MS, meaning that eligible patients must have recently experienced multiple MS relapses and/or displayed enhancing lesions on their MRI images (enhancing lesions are indicators of immune activity within the central nervous system). (wheelchairkamikaze.com)
  • Since this excludes many secondary progressive (SPMS) and most primary progressive (PPMS) patients, who experience increasing disability in the complete absence of relapses or enhancing lesions, these requirements are understandably the source of much consternation among this patient population (myself included), who are currently presented with no effective treatment options. (wheelchairkamikaze.com)
  • Coronal fluid-attenuated inversion recovery (FLAIR) MRI in a patient with multiple sclerosis demonstrates periventricular high-signal intensity lesions, which exhibit a typical distribution for multiple sclerosis. (medscape.com)
  • Axial diffusion-weighted MRI in a patient with multiple sclerosis shows several hyperintense lesions, a feature of inflammatory disease activity. (medscape.com)
  • In addition, depending on the number and location of findings, MRI can vary greatly in terms of sensitivity and specificity in the diagnosis of MS. This is especially true of primary progressive MS, which may not show the classic discrete lesions of relapsing-remitting MS. (medscape.com)
  • Plain radiographic studies have no positive predictive value in the diagnosis of multiple sclerosis, but occasionally, plain radiographs may be used to exclude mechanical bony lesions. (medscape.com)
  • At this point I would rarely escalate treatment for progressive disability unless it was accompanied by attacks or evidence of active inflammatory lesions on MRI," he said. (medscape.com)
  • METHODS: Using MSBase, a large international, observational, prospectively acquired cohort study, we identified patients with relapsing-remitting multiple sclerosis experiencing relapses or disability progression within the 6 months immediately preceding switch to either natalizumab or fingolimod. (unich.it)
  • Fenebrutinib's mechanism of action, which can inhibit both B cells and microglia, has the potential to both reduce MS disease activity, such as relapses, and also impact disease progression. (gene.com)
  • This dual inhibition has the potential to reduce both MS disease activity and progression, thereby addressing the key unmet medical need in people living with MS. The Phase III program includes two identical trials in RMS (FENhance 1 and 2) with an active teriflunomide comparator and one trial in PPMS (FENtrepid) in which fenebrutinib is being evaluated against Ocrevus ® (ocrelizumab). (gene.com)
  • Four years after treatment, 80% of trial subjects remained relapse free, and 87% showed no signs of disease progression. (wheelchairkamikaze.com)
  • With the advent of newer disease-modifying therapies (DMTs), treatment goals are to reduce relapse frequency and MRI disease activity, and ultimately limit progression of disability . (medscape.com)
  • 3 .Relapse is more strongly associated with elevated csf nfl than the development of progression. (ecs-acc.com)
  • The annualized relapse rates decreased from 1.5 to 0.2 on natalizumab and from 1.3 to 0.4 on fingolimod, with 50% relative postswitch difference in relapse hazard (p? (unich.it)
  • In CARE-MS I, Genzyme said, Lemtrada was significantly more effective than interferon beta-1a at reducing annualized relapse rates. (genengnews.com)
  • In CARE-MS II, Lemtrada was significantly more effective than interferon beta-1a at reducing annualized relapse rates, and accumulation of disability was significantly slowed in patients given Lemtrada vs. interferon beta-1a, according to the company. (genengnews.com)
  • EU approval of Aubagio includes a new active substance designation, and was based on data from the Phase III TEMSO (TEriflunomide Multiple Sclerosis Oral) and TOWER (Teriflunomide Oral in people With relapsing remitting multiplE scleRosis) trials. (genengnews.com)
  • In the US, it is additionally approved for other relapsing forms of MS such as clinically isolated syndrome and active secondary progressive disease. (wikipedia.org)
  • Treatment of relapsing forms of MS, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. (drugs.com)
  • Glatopa is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. (rxlist.com)
  • Tyruko was approved to treat adults with clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. (medicalxpress.com)
  • New diagnostic criteria have enabled the multiple sclerosis diagnosis in many patients at the first clinical demyelinating event, clinically isolated syndrome. (ku.dk)
  • The remaining patients with clinically isolated syndrome have a more benign prognosis, and for relapsing-remitting multiple sclerosis, the prognosis has become more favourable. (ku.dk)
  • Monomethyl fumarate is used to treat relapsing forms of multiple sclerosis in adults (including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease). (everydayhealth.com)
  • Ofatumumab is a drug used to treat adult patients with relapsing-remitting multiple sclerosis that includes clinically isolated syndrome, relapsing-remitting, and secondary progressive active form. (dominicantoday.com)
  • Masitinib is a selective tyrosine kinase inhibitor, targeting innate immune cells (mast cells and microglia) that are involved in the pathophysiology of progressive multiple sclerosis (MS). This is a multicenter, double-blind, randomized, placebo-controlled, comparative study of oral masitinib in the treatment of patients with progressive MS who were progressing but not clinically active. (ichgcp.net)
  • In August 2020, the US FDA approved Kesimpta® (as an injection for subcutaneous use for the treatment of relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. (justpaste.it)
  • A recent MRI scan showed she had no signs of the active disease and clinically she has had no further relapses since receiving this treatment. (sheffield.ac.uk)
  • The National Multiple Sclerosis Society estimates that more than 2.3 million people worldwide have MS. That includes an estimated 1 million people in the United States , according to a 2017 study by the Society. (healthline.com)
  • Delivering the Donald Paty Memorial Lecture at the Consortium of Multiple Sclerosis Centers (CMSC) 2017 Annual Meeting, Brian G. Weinshenker, MD, professor of neurology at the Mayo Clinic, Rochester, argues that despite the robust efficacy of the newer agents, they are not warranted in all patients. (medscape.com)
  • Evidence-based recommendations on alemtuzumab (Lemtrada) for treating highly active relapsing-remitting multiple sclerosis in adults. (nice.org.uk)
  • On 16 September 2021, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Vumerity, intended for the treatment of adults with relapsing remitting multiple sclerosis. (wikipedia.org)
  • OTCQX: RHHBY), announced today positive results from the Phase II FENopta study evaluating investigational oral fenebrutinib in adults with relapsing forms of multiple sclerosis (RMS). (gene.com)
  • Children and teens with multiple sclerosis are treated with the same therapies as adults, but they are considered "off label" for treating children, (not an FDA approved the use of the drug, but it is/may be effective for some people with the condition). (medicinenet.com)
  • On the other hand, siponimod will treat adults with an advanced form of multiple sclerosis, known as secondary active-phase multiple sclerosis. (dominicantoday.com)
  • 3 Last week, NICE issued a Final Appraisal Determination (FAD) that recommends cladribine tablets as an option for treating highly active MS in adults. (acnr.co.uk)
  • Tecfidera is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS) in adults. (nicerx.com)
  • whereas, MS is typically a chronic relapsing and remitting disease of young adults. (medscape.com)
  • 16 Runia T.F., van Pelt-Gravesteijn E.D., Hintzen R.Q. Recent gains in clinical multiple sclerosis research review. (thieme-connect.de)
  • One important question that is yet to be definitively answered is how AHSCT stacks up as a treatment against the new generation, highly efficacious therapies available for relapsing MS. However, to date there have been limited clinical trials comparing the success rate of AHSCT with more conventional treatments of relapsing remitting MS. (msaustralia.org.au)
  • To date, more than 2,400 patients and healthy volunteers have been treated with fenebrutinib in Phase I, II and III clinical programs across multiple diseases, including MS and other autoimmune disorders. (gene.com)
  • Glatopa (glatiramer acetate injection) is an immunomodulator used to treat patients with relapsing forms of multiple sclerosis (MS), including those who have experienced a first clinical episode and have magnetic resonance imaging (MRI) features consistent with MS. Glatopa is generic version of Copaxone . (rxlist.com)
  • Reduced disease activity in patients with relapsing-remitting multiple sclerosis can partly be ascribed to more efficacious new disease-modifying therapies but decrease in disease activity has also be seen in placebo-treated patients in clinical trials. (ku.dk)
  • This week 70 physicians from Central America and the Caribbean will participate in a hybrid meeting with 12 international experts to analyze clinical evidence in the approach to multiple sclerosis. (dominicantoday.com)
  • This study demonstrates the utility of MSM in emulating trials to compare clinical effectiveness among multiple interventions simultaneously. (unipr.it)
  • Relapsing forms of MS include active secondary MS (defined as a clinical relapse or new lesion seen on an MRI scan of the brain or spinal cord). (msdmanuals.com)
  • [ 37 , 46 , 48 ] ADEM bears a striking clinical and pathological resemblance to other acute demyelinating syndromes (ADS) of childhood, including multiple sclerosis (MS). ADEM in children is readily distinguishable from alternative diagnoses on the basis of clinical features and findings on neuroimaging and laboratory investigations. (medscape.com)
  • Combining Clinical and Genetic Data to Predict Response to Fingolimod Treatment in Relapsing Remitting Multiple Sclerosis Patients: A Precision Medicine Approach. (cdc.gov)
  • Use of cladribine tablets is recommended only if a person has rapidly evolving severe relapsing-remitting multiple sclerosis, that is, at least two relapses in the previous year and at least one T1 gadolinium-enhancing lesion at baseline MRI or relapsing-remitting multiple sclerosis that has responded inadequately to treatment with disease-modifying therapy, defined as one relapse in the previous year and MRI evidence of disease activity. (acnr.co.uk)
  • INTERPRETATION: This study suggests that in active multiple sclerosis during treatment with injectable disease-modifying therapies, switching to natalizumab is more effective than switching to fingolimod in reducing relapse rate and short-term disability burden. (unich.it)
  • Like Tysabri, the biosimilar is also indicated for treating moderately to severely active Crohn disease in patients who do not respond to or tolerate conventional Crohn disease therapies or tumor necrosis factor-alpha inhibitors. (medicalxpress.com)
  • Also, an increasing tendency to treat progressive multiple sclerosis with disease-modifying therapies may have contributed to change the course in progressive multiple sclerosis. (ku.dk)
  • This will be a space for the medical community to discuss advances in therapies to treat multiple sclerosis (MS), a disease affecting more than 2.8 million people worldwide. (dominicantoday.com)
  • Compared with glatiramer acetate (reference), several therapies showed a superior ATE in reducing relapses: natalizumab (HR=0.44, 95% CI=0.40 to 0.50), fingolimod (HR=0.60, 95% CI=0.54 to 0.66) and dimethyl fumarate (HR=0.78, 95% CI=0.66 to 0.92). (unipr.it)
  • Approximately two-thirds of patients in each group remained relapse free. (amsterdamumc.org)
  • The epidemiology of multiple sclerosis in Europe. (thieme-connect.de)
  • The natural history of multiple sclerosis appears milder from the first sign of demyelinating disease to the progressive course, probably as a result of an interplay between several factors including changes in the diagnostic criteria, changes in the epidemiology of multiple sclerosis, impact of early and appropriate disease-modifying treatment and improvement of the general state of health in the population. (ku.dk)
  • Subgroups were defined based on demographics, disease characteristics (baseline EDSS score, relapse rate, and MRI parameters), and response to previous therapy. (nih.gov)
  • Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS) , which includes the brain , spinal cord , and optic nerve . (healthline.com)
  • Multiple sclerosis is a chronic neurological disease of an inflammatory and autoimmune nature that affects the central nervous system, i.e., the brain and spinal cord. (dominicantoday.com)
  • Multiple Sclerosis (MS) is a chronic inflammatory demyelinating and neurodegenerative disease of the central nervous system (CNS) of supposed autoimmune origin, which is currently believed to be mediated by a combined attack directed by both T and B cells [ 1 ]. (biomedcentral.com)
  • ˆ ` ´ ´ Jerome De Seze Gilles Defer Frederic Sedel Carl Arndt Published online: 28 May 2018 The Author(s) 2018 Abstract Objective The aim of this study was to evaluate whether Background Chronic visual loss is a disabling feature in MD1003 improves vision compared with placebo in MS patients with multiple sclerosis (MS). It was recently patients with chronic visual loss. (deepdyve.com)
  • Switch to natalizumab vs fingolimod in active relapsing-remitting multiple sclerosis. (unich.it)
  • Natalizumab reduces relapses in patients with active multiple sclerosis (MS), but recent studies report severe worsening of MS after suspension of treatment, as a consequence of the rebound effect. (thieme-connect.de)
  • Conclusion Relapses of MS after discontinuation of natalizumab treatment indicate rebound of disease activity, supporting the homeopathic principle and warning healthcare professionals about this serious iatrogenic event. (thieme-connect.de)
  • 15 Horga A., Tintoré M. Natalizumab for relapsing-remitting multiple sclerosis. (thieme-connect.de)
  • 18 Kleinschmidt-DeMasters B.K., Miravalle A., Schowinsky J., Corboy J., Vollmer T. Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab. (thieme-connect.de)
  • Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis. (msaustralia.org.au)
  • The U.S. Food and Drug Administration approved Tyruko (natalizumab-sztn), the first biosimilar to Tysabri (natalizumab) injection, for the treatment of relapsing forms of multiple sclerosis, the agency announced Thursday. (medicalxpress.com)
  • The pairwise ATT comparisons also showed superior effects of natalizumab followed by fingolimod on relapses and disability. (unipr.it)
  • Diroximel fumarate, sold under the brand name Vumerity, is a medication used for the treatment of relapsing forms of multiple sclerosis (MS). It acts as an immunosuppressant and anti-inflammatory drug. (wikipedia.org)
  • Diroximel fumarate is used for the treatment of relapsing-remitting multiple sclerosis. (wikipedia.org)
  • Do not initiate treatment in patients with an active infection until the infection is resolved. (drugs.com)
  • This treatment has been used to treat highly active inflammatory MS for over two decades. (msaustralia.org.au)
  • Biosimilar medications offer additional effective treatment options that have the potential to increase access for people living with relapsing forms of multiple sclerosis," Paul R. Lee, M.D., Ph.D., of the FDA Center for Drug Evaluation and Research, said in an agency news release. (medicalxpress.com)
  • The activity was organized by Novartis and supported by the Latin American Committee for Treatment and Research in Multiple Sclerosis (LACTRIMS), the Central American and the Caribbean Committee for Treatment and Research in Multiple Sclerosis (CACTRIMS), and the Central American and Caribbean Forum on Multiple Sclerosis (FOCEM), will take place on August 26 and 27 and will be held in Santo Domingo, Dominican Republic. (dominicantoday.com)
  • To evaluate the efficacy and safety of oral masitinib versus placebo in the treatment of patients with primary progressive or secondary progressive multiple sclerosis without relapse. (ichgcp.net)
  • Moreover, the US Food and Drug Administration (FDA) is a highly active regulatory body which focuses on not only on the careful regulation of the approval processes of the medical devices and pharmaceutical products but also engages extensively in educating patients and caregivers regarding new treatment methods, products, and even adversities related to them. (justpaste.it)
  • Multiple sclerosis (MS) is a frequent and disabling neu- Treatment was overall well tolerated. (deepdyve.com)
  • Over the last six months or so, there has been a wave of new and encouraging research published regarding HSCT (Hematopoietic Stem Cell Therapy) for the treatment of multiple sclerosis. (wheelchairkamikaze.com)
  • Because HSCT is directed entirely at replacing a patient's presumably defective immune system with a new one that doesn't attack the body's own nervous system cells, the prevailing thinking is that only patients displaying the hallmarks of immune system driven multiple sclerosis would likely respond well to the treatment. (wheelchairkamikaze.com)
  • Marginal structural Cox models (MSMs) were used to estimate the average treatment effects (ATEs) and the average treatment effects among the treated (ATT), rebalancing the compared groups at 6-monthly intervals on age, sex, birth-year, pregnancy status, treatment, relapses, disease duration, disability and disease course. (unipr.it)
  • A team from Sheffield Teaching Hospitals NHS Foundation Trust led by two University of Sheffield Honorary Professors, are pioneering a breakthrough treatment in the UK for multiple sclerosis (MS). (sheffield.ac.uk)
  • A world-first trial is investigating if stem cell transplantation could be used in patients with aggressive multiple sclerosis (MS) as a first-line treatment. (sheffield.ac.uk)
  • So far the treatment has had a life-changing impact on patients who have the relapsing-remitting form of the disease. (sheffield.ac.uk)
  • [ 1 ] Magnetic resonance imaging (MRI) of the brain is useful in the diagnosis and treatment of multiple sclerosis . (medscape.com)
  • Magnetic resonance imaging (MRI) of the brain is useful in the diagnosis and treatment of multiple sclerosis (MS), an inflammatory, demyelinating condition of the central nervous system (CNS) that is generally considered to be autoimmune in nature. (medscape.com)
  • Prediction of Hemorrhagic Complication after Thrombolytic Therapy Based on Multimodal Data from Multiple Centers: An Approach to Machine Learning and System Implementation. (cdc.gov)
  • In response to the evolving needs of the community, You Don't Know Jack About MS ® launched an enhanced online destination featuring new content, resources, and docu-series chronicling Jack's journey with relapsing-remitting MS designed to help MS patients, caregivers and loved ones learn how to navigate through diagnosis and living with the disease. (tevausa.com)
  • Since my diagnosis three years ago, I have found so much satisfaction in helping others better understand MS, and I hope the new content inspires others who are living with MS to take an active role in how they manage their disease. (tevausa.com)
  • active secondary progressive disease (later stage of disease with continuous worsening of symptoms). (medlineplus.gov)
  • Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-beta1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients. (jci.org)
  • In animals with experimental autoimmune disease, a major mechanism of oral tolerance triggered by oral administration of antigen involves the induction of regulatory T cells that mediate active suppression by secreting the cytokine TGF-beta 1. (jci.org)
  • Multiple sclerosis ( MS ) is a disease that causes demyelination (disruption of the myelin that insulates and protects nerve cells) of spinal nerve and brain cells. (medicinenet.com)
  • Multiple sclerosis is a disease that involves an immune-mediated process that results in an abnormal response in the body's immune system that damages central nervous system (CNS) tissues in which the immune system attacks myelin, the substance that surrounds and insulates nerve fibers causing demyelination that leads to nerve damage. (medicinenet.com)
  • The immune system reacts erroneously against myelin (a fatty substance that covers and allows a nerve to transmit its impulses rapidly) in multiple areas, sometimes leaving scars (sclerosis). (dominicantoday.com)
  • Specifically, 4,860 short-term T cell lines were generated to either MBP, PLP, or tetanus toxoid (TT) from 34 relapsing-remitting MS patients: 17 orally treated with bovine myelin daily for a minimum of 2 yr as compared to 17 nontreated patients. (jci.org)
  • Multiple sclerosis (MS) is an immune-mediated inflammatory disease that attacks myelinated axons in the central nervous system, destroying the myelin and the axon in variable degrees and producing significant physical disability within 20-25 years in more than 30% of patients. (medscape.com)
  • There is growing evidence for the concept of multiple sclerosis (MS) as an inflammatory neurodegenerative disease, with a different pattern of atrophy evolution in grey matter (GM) and white matter (WM) tissue compartments. (bmj.com)
  • Multiple sclerosis (MS) is an immune-mediated inflammatory disease that attacks myelinated axons in the central nervous system (CNS) and often causes significant physical disability over time. (medscape.com)
  • Relapse rates in placebo groups in MS trials are also falling. (medscape.com)
  • After ingestion, the substance is cleaved by esterase enzymes before reaching the systemic circulation, resulting in monomethyl fumarate (MMF), the active metabolite, and hydroxyethyl succinimide (HES), which is inactive. (wikipedia.org)
  • This may be explained by several factors: change in the diagnostic criteria, more explicit inclusion criteria, exclusion of high-risk patients e.g. patients with co-morbidities, and more rigorous definitions of relapses and disease worsening. (ku.dk)
  • The American Academy of Neurology (AAN) recommends that disease-modifying therapy be offered to patients with relapsing forms of MS who have had recent relapses and/or MRI activity. (drugs.com)
  • Furthermore, according to the National Multiple Sclerosis Society, United States, in 2021, it has been estimated that about one million people are currently living in the country with MS, which is twice the number than previous estimates. (justpaste.it)
  • Because the exact antigen or target of the immune-mediated attack is not known, many experts prefer to label multiple sclerosis as 'immune-mediated instead of an autoimmune disease. (medicinenet.com)
  • MS, on the other hand, typically manifests as a relapsing-remitting illness in ensuing adolescence or young adulthood, a significant and unexplained latency of effect with apparent permanency of immune dysregulation. (medscape.com)
  • In conclusion, during the past decade the entire course of multiple sclerosis from the first sign of a demyelinating disorder through the progressive course appears to be milder due to a complex interplay of several factors. (ku.dk)
  • The purpose of this study was to investigate intrathecal production and affinity distributions of Epstein-Barr virus (EBV)-specific antibodies in multiple sclerosis (MS) and controls. (biomedcentral.com)
  • As evidenced by published research, virtual reality technology solutions in rehabilitation management actually add significantly to patients' self-motivation, while promoting their active involvement in therapy through visual, auditory, and kinaesthetic stimuli. (bvsalud.org)
  • If you have a form of relapsing MS, your doctor may have prescribed Tecfidera to you. (nicerx.com)
  • Genzyme is pursuing a supplemental Biologics License Application, seeking U.S. approval of Lemtrada for relapsing MS from the FDA, which is expected to take action later this year. (genengnews.com)
  • Relapse and disability outcomes were compared in paired, pairwise-censored analyses. (unich.it)
  • The outcomes analysed were incidence of relapses, 12-month confirmed disability worsening and improvement. (unipr.it)
  • Evidence suggests that it can be effective in treating people with relapsing remitting MS where they have failed to respond to more conventional disease modifying treatments. (msaustralia.org.au)
  • The effectiveness of disease-modifying drugs has reduced the transition from relapsing-remitting to secondary progressive multiple sclerosis. (ku.dk)
  • The concept of progressive multiple sclerosis has also evolved from two very distinct categories (primary progressive and secondary progressive multiple sclerosis) to a unified category of progressive multiple sclerosis, which can then be split into the categories of active or inactive. (ku.dk)
  • For some people, the disease is characterized by periods of relapse and remission, while others have a progressive pattern. (dominicantoday.com)
  • In addition, change in the therapeutic target to stable disease (no evidence of disease activity = no relapses, no disease worsening and no MRI activity) could by itself change the course in relapsing-remitting multiple sclerosis. (ku.dk)
  • Monitoring disease activity in Relapsing remitting Multiple Sclerosis. (ecs-acc.com)
  • NEW ORLEANS - With numerous agents for multiple sclerosis (MS) seemingly more effective in halting disease activity than the older "platform" drugs, can a case be made for starting almost all patients with newly diagnosed MS on them? (medscape.com)